epha.health
Feedback
Nuevo Caso
Registro
busy
3
Drogas
|
1
0
Hallazgos
|
Proceder

Consejo farmacológico para alprazolam, ketoconazol y carbamazepina

plan
Impresión
Version 6.0.32 (Beta Preview)

Resumen Resumen info 51%

Farmacocinética -17%
Alprazolam
Ketoconazol
Carbamazepina
Puntuaciones -7%
Extensión de tiempo QT
Efectos anticolinérgicos
Efectos serotoninérgicos
Efectos adversos de las drogas -25%
Somnolencia
Ataxia
Sedación

Variantes ✨

Para la evaluación computacionalmente intensiva de las variantes, elija la suscripción estándar paga.

medicamento Áreas de aplicación

Explicaciones para pacientes

undefined Farmacocinética info -17%

∑ Exposiciónaalpketcar
Alprazolam 0.48 2.06 0.38
Ketoconazol 0.29 1 0.29
Carbamazepina 1.1 [1.1,1.67] 1 1 1.1
Genotipos relevantes: 1CYP2C9
Símbolo (a): cambio de x veces en AUC
Leyenda (n.a.): Información no disponible

Los cambios en la exposición mencionados se refieren a cambios en la curva de concentración plasmática-tiempo [AUC]. La exposición a carbamazepina aumenta al 110%, cuando se combina con alprazolam (100%) y ketoconazol (110%). El AUC está entre 110% y 167% dependiendo del CYP2C9. La exposición a alprazolam se reduce al 48%. cuando se combina con ketoconazol (206%) y carbamazepina (38%). Esto puede estar asociado con una eficacia reducida. La exposición a ketoconazol se reduce al 29%. cuando se combina con alprazolam (100%) y carbamazepina (29%). Esto puede estar asociado con una eficacia reducida.

Clasificación: Los parámetros farmacocinéticos de la población media se utilizan como punto de partida para calcular los cambios individuales en la exposición debidos a las interacciones.
La alprazolam tiene una alta biodisponibilidad oral [ F ] del 88%, por lo que los niveles plasmáticos máximos [Cmax] tienden a cambiar poco durante una interacción. La vida media terminal [ t12 ] es de 11.7 horas y se alcanzan niveles plasmáticos constantes [ Css ] después de aproximadamente 46.8 horas. La unión a proteínas [ Pb ] es moderadamente fuerte al 70.2% y el volumen de distribución [ Vd ] es de 50 litros en el rango medio, Dado que la sustancia tiene una tasa de extracción hepática baja de 0,9, el desplazamiento de la unión a proteínas [Pb] en el contexto de una interacción puede aumentar la exposición. El metabolismo tiene lugar principalmente a través de CYP3A4..
La ketoconazol tiene una biodisponibilidad oral media [ F ] del 67%, por lo que los niveles plasmáticos máximos [Cmax] tienden a cambiar con una interacción. La vida media terminal [ t12 ] es bastante corta a las 5 horas y se alcanzan rápidamente niveles plasmáticos constantes [ Css ]. La unión a proteínas [ Pb ] es moderadamente fuerte al 91.5% y el volumen de distribución [ Vd ] es muy grande a 84 litros, Dado que la sustancia tiene una tasa de extracción hepática baja de 0,9, el desplazamiento de la unión a proteínas [Pb] en el contexto de una interacción puede aumentar la exposición. El metabolismo tiene lugar principalmente a través de CYP3A4. y el transporte activo tiene lugar en particular a través de PGP.
La carbamazepina tiene una biodisponibilidad oral media [ F ] del 78%, por lo que los niveles plasmáticos máximos [Cmax] tienden a cambiar con una interacción. La vida media terminal [ t12 ] es de 20 horas y se alcanzan niveles plasmáticos constantes [ Css ] después de aproximadamente 80 horas. La unión a proteínas [ Pb ] es moderadamente fuerte al 77.2% y el volumen de distribución [ Vd ] es muy grande a 90 litros, Dado que la sustancia tiene una tasa de extracción hepática baja de 0,9, el desplazamiento de la unión a proteínas [Pb] en el contexto de una interacción puede aumentar la exposición. El metabolismo tiene lugar a través de CYP1A2, CYP2C8, CYP2C9 y CYP3A4, entre otros..

transmisor Efectos serotoninérgicos info -0%

Puntuaciones ∑ Puntos alpketcar
Efectos serotoninérgicos a 0 Ø Ø Ø
Símbolo (a): Riesgo aumentado desde 5 puntos.

Clasificación: Según nuestro conocimiento, ni la alprazolam, ketoconazol ni la carbamazepina aumentan la actividad serotoninérgica.

transmisor Efectos anticolinérgicos info -7%

Puntuaciones ∑ Puntos alpketcar
Kiesel b 3+Ø++
Símbolo (b): Mayor riesgo de 3 puntos.

Recomendación: El riesgo de efectos secundarios anticolinérgicos como visión borrosa, confusión y temblor aumenta con esta terapia. Si es posible, se debe cambiar la terapia o se debe vigilar de cerca al paciente para detectar otros síntomas como Se controlan el estreñimiento, la midriasis y la vigilancia reducida.

Clasificación: Juntas, la carbamazepina (moderar) y la alprazolam (leve) aumentan la actividad anticolinérgica. Según nuestros hallazgos, la ketoconazol no aumenta la actividad anticolinérgica.

electrocardiograma Extensión de tiempo QT info -0%

Puntuaciones ∑ Puntos alpketcar
RISK-PATH c 0.25Ø+Ø
Símbolo (c): Riesgo aumentado desde 10 puntos.

Recomendación: Asegúrese de minimizar los factores de riesgo influibles. Las alteraciones electrolíticas, como los bajos niveles de calcio, potasio y magnesio, deben compensarse. Se debe usar la dosis efectiva más baja de ketoconazol.

Clasificación: La ketoconazol puede prolongar potencialmente el tiempo QT y, si hay factores de riesgo, se pueden favorecer las arritmias del tipo torsades de pointes. No conocemos ningún potencial de prolongación del intervalo QT para alprazolam y carbamazepina.

Otros efectos secundarios Efectos secundarios generales info -25%

Efectos secundarios ∑ frecuencia alpketcar
Somnolencia54.9 %49.9↓n.a.10.0
Ataxia50.0 %n.a.n.a.50.0
Sedación45.2 %45.2↓n.a.n.a.
Mareo44.6 %20.8↓n.a.30.0
Fatiga38.1 %31.3↓n.a.10.0
Problema de coordinación24.8 %24.8↓n.a.n.a.
Deterioro de la memoria24.3 %24.3↓n.a.n.a.
Apetito incrementado19.9 %19.9↓n.a.n.a.
Estreñimiento17.1 %17.1↓n.a.n.a.
Disartria17.1 %17.1↓n.a.n.a.
Extracto tabular de los efectos secundarios más comunes.
Signo (+): efecto adverso descrito, pero frecuencia no conocida
Signo (↑/↓): frecuencia bastante más alta / más baja debido a la exposición

Metabólico
Aumento de peso (14.9%): alprazolam

Gastrointestinal
Xerostomía (13.3%): carbamazepina, alprazolam
Náusea (8.9%): carbamazepina, ketoconazol
Vómitos (8.9%): carbamazepina, ketoconazol

Mental
Depresión (11.7%): alprazolam
Irritabilidad: alprazolam
Efecto rebote: alprazolam
Adicción: alprazolam

Sistema reproductivo
Reduccion de la libido (10.2%): alprazolam

Dermatológico
Reacciones alérgicas de la piel (10%): carbamazepina
Sensacion de quemarse: ketoconazol
Prurito: ketoconazol
Erupción: ketoconazol
Síndrome de Stevens-Johnson: carbamazepina, alprazolam
Necrolisis epidérmica toxica: carbamazepina

Neurológico
Confusión (6%): alprazolam

Oftalmológico
Visión borrosa (5.5%): carbamazepina
Nistagmo: carbamazepina

Hematológico
Leucopenia (2%): carbamazepina
Eosinofilia: carbamazepina
Trombocitopenia: carbamazepina
Agranulocitosis: carbamazepina
Mielosupresión: carbamazepina

Cardíaco
Hipotension: carbamazepina
Bloqueo auriculoventricular: carbamazepina
Arritmia ventricular: ketoconazol

Electrolitos
Hiponatremia: carbamazepina
Hiperpotasemia: ketoconazol

Vascular
Edema periférico: carbamazepina
Tromboflebitis: carbamazepina

Endocrino
Insuficiencia suprarrenal: ketoconazol

Hepático
Hepatitis colestásica: carbamazepina
Síndrome de los conductillos biliares evanescentes: carbamazepina
Insuficiencia hepática: alprazolam
Hepatotoxicidad: ketoconazol

Inmunológico
Reacción de hipersensibilidad: carbamazepina, ketoconazol

Renal
Nefritis tubulointersticial: carbamazepina

Limitaciones Limitaciones

Con base en sus e información científica, evaluamos el riesgo individual de efectos secundarios adversos. Las barras naranjas indican el potencial básico de los medicamentos para causar este efecto secundario. Estas recomendaciones están destinadas a asesorar a los profesionales y no sustituyen la consulta con un médico. En la versión de prueba restringida (alfa), el riesgo de todas las sustancias aún no se ha evaluado de manera concluyente.

literatura Referencias de literatura

1. Grimsley SR et al. Increased carbamazepine plasma concentrations after fluoxetine coadministration. Clinical pharmacology and therapeutics. 1991
Authors: Grimsley SR Jann MW Carter JG D'Mello AP D'Souza MJ
Abstract: The interaction between fluoxetine and carbamazepine was investigated in six normal, healthy male volunteers (aged 23 to 40 years). Subjects were given carbamazepine, 400 mg every morning, for 3 weeks. Venous carbamazepine blood samples were obtained at baseline and 1, 2, 4, 6, 8, 10, 12, and 24 hours after the morning dose. Fluoxetine, 20 mg every morning, was then coadministered with carbamazepine for 7 days. Venous carbamazepine blood samples were again obtained as described. Carbamazepine and carbamazepine-10,11-epoxide (CBZE) were assayed by HPLC. Addition of fluoxetine resulted in a significant increase in the area under the concentration-time curve of carbamazepine (105.93 +/- 18.05 micrograms/ml.hr versus 134.97 +/- 12.15 micrograms/ml.hr; t = 3.284; df = 5; p = 0.022) and CBZE (11.6 +/- 1.93 micrograms/ml.hr versus 15.2 +/- 2.4 micrograms/ml.hr; t = 2.805; df = 5; p = 0.038). Both oral and intrinsic clearance of carbamazepine was decreased significantly on fluoxetine addition (3.87 +/- 0.68 L/hr versus 2.98 +/- 0.26 L/hr; t = 3.025; df = 5; p = 0.029 and 17.90 +/- 4.9 L/hr versus 11.92 +/- 1.4 L/hr; t = 3.037; df = 5; p = 0.029, respectively). No significant changes were determined for fraction of absorbed dose, volume of distribution, absorption rate constant, and elimination rate constant. These findings suggest that fluoxetine can inhibit the metabolism of carbamazepine. Careful monitoring of patients is recommended when these two drugs are coadministered.
Pubmed Id: 1855347
2. Fraser AD et al. Urinary screening for alprazolam and its major metabolites by the Abbott ADx and TDx analyzers with confirmation by GC/MS. Journal of analytical toxicology.
Authors: Fraser AD Bryan W Isner AF
Abstract: Alprazolam is a short-acting triazolobenzodiazepine with anxiolytic and antidepressant properties. It has a half-life of 10-15 hours after multiple oral doses. Approximately 20% of an oral dose is excreted unchanged in the urine. The major urinary metabolites are alpha-OH alprazolam glucuronide and 3-HMB benzophenone glucuronide. The objective of this study was to characterize the reactivity of alprazolam and three metabolites in the Abbott ADx and TDx urinary benzodiazepine assays compared with the EMIT d.a.u. benzodiazepine assay. Alprazolam (at 300 ng/mL) gave an equivalent response as the 300 ng/mL low control (nordiazepam). alpha-OH alprazolam gave an equivalent response to this control between 300-500 ng/mL and 4-OH alprazolam between 500-1000 ng/mL. The 3-HMB benzophenone was not positive even at 10,000 ng/mL. The ADx screening assay was positive in 26 of 31 urine specimens collected from alprazolam-treated patients. All 31 of these specimens were confirmed positive for alpha-OH alprazolam by GC/MS after enzymatic hydrolysis and formation of a TMS derivative. For the TDx, 27 of 31 specimens were positive for benzodiazepines and all 31 were confirmed by GC/MS. All 5 of the negative ADx specimens and 4 of 5 TDx specimens contained 150-400 ng/mL of alpha-OH alprazolam. In conclusion, both the ADx and TDx urine benzodiazepine assays are acceptable screening assays for alprazolam use when the alpha-OH alprazolam concentration is greater than 400 ng/mL.
Pubmed Id: 2046338
3. Fawcett JA et al. Alprazolam: pharmacokinetics, clinical efficacy, and mechanism of action. Pharmacotherapy.
Authors: Fawcett JA Kravitz HM
Abstract: Alprazolam, a triazolobenzodiazepine, is the first of this new class of benzodiazepine drugs to be marketed in the United States and Canada. It achieves peak serum levels in 0.7 to 2.1 hours and has a serum half-life of 12 to 15 hours. When given in the recommended daily dosage of 0.5 to 4.0 mg, it is as effective as diazepam and chlordiazepoxide as an anxiolytic agent. Its currently approved indication is for the treatment of anxiety disorders and symptoms of anxiety, including anxiety associated with depression. Although currently not approved for the treatment of depressive disorders, studies published to date have demonstrated that alprazolam compares favorably with standard tricyclic antidepressants. Also undergoing investigation is the potential role of alprazolam in the treatment of panic disorders. Alprazolam has been used in elderly patients with beneficial results and a low frequency of adverse reactions. Its primary side effect, drowsiness, is less than that produced by diazepam at comparable doses. Data on toxicity, tolerance, and withdrawal profile are limited, but alprazolam seems to be at least comparable to other benzodiazepines. Drug interaction data are also limited, and care should be exercised when prescribing alprazolam for patients taking other psychotropic drugs because of potential additive depressant effects.
Pubmed Id: 6133268
4. Smith RB et al. Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration. Psychopharmacology. 1984
Authors: Smith RB Kroboth PD Vanderlugt JT Phillips JP Juhl RP
Abstract: Six fasting male subjects (20-32 years of age) received an oral tablet and an IV 1.0-mg dose of alprazolam in a crossover-design study. Alprazolam plasma concentration in multiple samples during 36 h after dosing was determined by electron-capture gas-liquid chromatography. Psychomotor performance tests, digit-symbol substitution (DSS), and perceptual speed (PS) were administered at 0, 1.25, 2.25, 5.0, and 12.5 h. Sedation was assessed by the subjects and by an observer using the Stanford Sleepiness Scale and a Nurse Rating Sedation Scale (NRSS), respectively. Mean kinetic parameters after IV and oral alprazolam were as follows: volume of distribution (Vd) 0.72 and 0.84 l/kg; elimination half-life (t1/2) 11.7 and 11.8 h; clearance (Cl) 0.74 and 0.89 ml/min/kg. There were no significant differences between IV and oral alprazolam in Vd, t1/2, or area under the curve. The mean fraction absorbed after oral administration was 0.92. Performance on PS and DSS tests was impaired at 1.25 and 2.5 h, but had returned to baseline at 5.0 h for both treatments. Onset of sedation was rapid after IV administration and the average time of peak sedation was 0.48 h. Sedation scores were significantly lower during hour 1 after oral administration than after IV, but were not significantly different at later times. Alprazolam is fully available after oral administration and kinetic parameters are not affected by route of administration. With the exception of rapidity of onset, the pharmacodynamic profiles of IV and oral alprazolam are very similar after a 1.0-mg dose.
Pubmed Id: 6152055
5. Kerr BM et al. Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochemical pharmacology. 1994
Authors: Kerr BM Thummel KE Wurden CJ Klein SM Kroetz DL Gonzalez FJ Levy RH
Abstract: A number of drugs inhibit the metabolism of carbamazepine catalyzed by cytochrome P450, sometimes resulting in carbamazepine intoxication. However, there is little information available concerning the identity of the specific isoforms of P450 responsible for the metabolism of this drug. This study addressed the role of CYP3A4 in the formation of carbamazepine-10,11-epoxide, the major metabolite of carbamazepine. Results of the study showed that: (1) purified CYP3A4 catalyzed 10,11-epoxidation; (2) cDNA-expressed CYP3A4 catalyzed 10,11-epoxidation (Vmax = 1730 pmol/min/nmol P450, Km = 442 microM); (3) the rate of 10,11-epoxidation correlated with CYP3A4 content in microsomes from sixteen human livers (r2 = 0.57, P < 0.001); (4) triacetyloleandomycin and anti-CYP3A4 IgG reduced 10,11-epoxidation to 31 +/- 6% (sixteen livers) and 43 +/- 2% (four livers) of control rates, respectively; and (5) microsomal 10,11-epoxidation but not phenol formation was activated 2- to 3-fold by alpha-naphthoflavone and progesterone and by carbamazepine itself (substrate activation). These findings indicate that CYP3A4 is the principal catalyst of 10,11-epoxide formation in human liver. Experiments utilizing a panel of P450 isoform selective inhibitors also suggested a minor involvement of CYP2C8 in liver microsomal 10,11-epoxidation. Epoxidation by CYP2C8 was confirmed in incubations of carbamazepine with cDNA-expressed CYP2C8. The role of CYP3A4 in the major pathway of carbamazepine elimination is consistent with the number of inhibitory drug interactions associated with its clinical use, interactions that result from a perturbation of CYP3A4 catalytic activity.
Pubmed Id: 8010982
6. Burstein AH et al. Lack of effect of St John's Wort on carbamazepine pharmacokinetics in healthy volunteers. Clinical pharmacology and therapeutics. 2000
Authors: Burstein AH Horton RL Dunn T Alfaro RM Piscitelli SC Theodore W
Abstract: BACKGROUND: St John's Wort is a popular herbal product used by approximately 7% of patients with epilepsy. Previous reports have described reductions in concentrations of CYP3A4 substrates indinavir and cyclosporine (INN, ciclosporin) associated with St John's Wort. OBJECTIVE: Our objective was to determine the effect of St John's Wort on steady state carbamazepine and carbamazepine-10,11-epoxide pharmacokinetics. METHODS AND SUBJECTS: Eight healthy volunteers (5 men; age range, 24-43 years) participated in this unblinded study. Subjects received 100 mg of carbamazepine twice daily for 3 days, 200 mg twice daily for 3 days, and then 400 mg once daily for 14 days. Blood samples were collected before and 1, 2, 4, 6, 8, 10, 12, and 24 hours after the dose on day 21. The subjects then took 300 mg of St John's Wort (0.3% hypericin standardized tablet) 3 times daily with meals and with carbamazepine for 14 days. On day 35, blood sampling was repeated. Plasma samples were analyzed for carbamazepine and carbamazepine-10,11-epoxide with HPLC. We compared carbamazepine and carbamazepine-10,11-epoxide noncompartmental pharmacokinetic parameter values before and after St John's Wort with a paired Student t test. RESULTS: We found no significant differences before or after the administration of St John's Wort in carbamazepine peak concentration (7.2 +/- 1 mg/L before versus 7.6 +/- 1.3 mg/L after), trough concentration (4.8 +/- 0.5 mg/L before versus 4.3 +/- 0.8 mg/L after), area under the plasma concentration-time curve (142.4 +/- 12.9 mg x h/L before versus 143.8 +/- 27.2 mg x h/L after), or oral clearance (2.8 +/- 0.3 L/h before versus 2.9 +/- 0.6 L/h after). Similarly, no differences were found in peak concentration (2 +/- 0.5 mg/L before versus 2.1 +/- 0.4 mg/L after), trough concentration (1.3 +/- 0.3 mg/L before versus 1.4 +/- 0.3 mg/L after), and area under the plasma concentration-time curve (37.5 +/- 7.4 mg x h/L before versus 41.9 +/- 10.3 mg x h/L after) of carbamazepine-10,11-epoxide. CONCLUSIONS: The results suggest that treatment with St John's Wort for 14 days did not further induce the clearance of carbamazepine.
Pubmed Id: 11180020
7. Mok NS et al. Ketoconazole induced torsades de pointes without concomitant use of QT interval-prolonging drug. Journal of cardiovascular electrophysiology. 2005
Authors: Mok NS Lo YK Tsui PT Lam CW
Abstract: Ketoconazole is not known to be proarrhythmic without concomitant use of QT interval-prolonging drugs. We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking ketoconazole for treatment of fungal infection. Her QT interval returned to normal upon withdrawal of ketoconazole. Genetic study did not find any mutation in her genes that encode cardiac IKr channel proteins. We postulate that by virtue of its direct blocking action on IKr, ketoconazole alone may prolong QT interval and induce TdP. This calls for attention when ketoconazole is administered to patients with risk factors for acquired long QT syndrome.
Pubmed Id: 16403073
8. Park JY et al. Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects. Clinical pharmacology and therapeutics. 2006
Authors: Park JY Kim KA Park PW Lee OJ Kang DK Shon JH Liu KH Shin JG
Abstract: OBJECTIVE: Our objective was to evaluate the effect of the CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy volunteers. METHODS: Nineteen healthy male volunteers were divided into 3 groups on the basis of the genetic polymorphism of CYP3A5. The groups comprised subjects with CYP3A5*1/*1 (n=5), CYP3A5*1/*3 (n=7), or CYP3A5*3/*3 (n=7). After a single oral 1-mg dose of alprazolam, plasma concentrations of alprazolam were measured up to 72 hours, together with assessment of psychomotor function by use of the Digit Symbol Substitution Test, according to CYP3A5 genotype. RESULTS: The area under the plasma concentration-time curve for alprazolam was significantly greater in subjects with CYP3A5*3/*3 (830.5+/-160.4 ng . h/mL [mean+/-SD]) than in those with CYP3A5*1/*1 (599.9+/-141.0 ng . h/mL) (P=.030). The oral clearance of alprazolam was also significantly different between the CYP3A5*1/*1 group (3.5+/-0.8 L/h) and CYP3A5*3/*3 group (2.5+/-0.5 L/h) (P=.036). Although a trend was noted for the area under the Digit Symbol Substitution Test score change-time curve (area under the effect curve) to be greater in subjects with CYP3A5*3/*3 (177.2+/-84.6) than in those with CYP3A5*1/*1 (107.5+/-44), the difference did not reach statistical significance (P=.148). CONCLUSIONS: The CYP3A5*3 genotype affects the disposition of alprazolam and thus influences the plasma levels of alprazolam.
Pubmed Id: 16765147
9. Sriwiriyajan S et al. Effect of efavirenz on the pharmacokinetics of ketoconazole in HIV-infected patients. European journal of clinical pharmacology. 2007
Authors: Sriwiriyajan S Mahatthanatrakul W Ridtitid W Jaruratanasirikul S
Abstract: OBJECTIVE: To investigate the effect of efavirenz on the ketoconazole pharmacokinetics in HIV-infected patients. METHODS: Twelve HIV-infected patients were assigned into a one-sequence, two-period pharmacokinetic interaction study. In phase one, the patients received 400 mg of ketoconazole as a single oral dose on day 1; in phase two, they received 600 mg of efavirenz once daily in combination with 150 mg of lamivudine and 30 or 40 mg of stavudine twice daily on days 2 to 16. On day 16, 400 mg of ketoconazole was added to the regimen as a single oral dose. Ketoconazole pharmacokinetics were studied on days 1 and 16. RESULTS: Pretreatment with efavirenz significantly increased the clearance of ketoconazole by 201%. C(max) and AUC(0-24) were significantly decreased by 44 and 72%, respectively. The T ((1/2)) was significantly shorter by 58%. CONCLUSION: Efavirenz has a strong inducing effect on the metabolism of ketoconazole.
Pubmed Id: 17345073
10. Sekar VJ et al. Pharmacokinetics of darunavir/ritonavir and ketoconazole following co-administration in HIV-healthy volunteers. British journal of clinical pharmacology. 2008
Authors: Sekar VJ Lefebvre E De Pauw M Vangeneugden T Hoetelmans RM
Abstract: AIMS: To investigate the interaction between ketoconazole and darunavir (alone and in combination with low-dose ritonavir), in HIV-healthy volunteers. METHODS: Volunteers received darunavir 400 mg bid and darunavir 400 mg bid plus ketoconazole 200 mg bid, in two sessions (Panel 1), or darunavir/ritonavir 400/100 mg bid, ketoconazole 200 mg bid and darunavir/ritonavir 400/100 mg bid plus ketoconazole 200 mg bid, over three sessions (Panel 2). Treatments were administered with food for 6 days. Steady-state pharmacokinetics following the morning dose on day 7 were compared between treatments. Short-term safety and tolerability were assessed. RESULTS: Based on least square means ratios (90% confidence intervals), during darunavir and ketoconazole co-administration, darunavir area under the curve (AUC(12h)), maximum plasma concentration (C(max)) and minimum plasma concentration (C(min)) increased by 155% (80, 261), 78% (28, 147) and 179% (58, 393), respectively, compared with treatment with darunavir alone. Darunavir AUC(12h), C(max) and C(min) increased by 42% (23, 65), 21% (4, 40) and 73% (39, 114), respectively, during darunavir/ritonavir and ketoconazole co-administration, relative to darunavir/ritonavir treatment. Ketoconazole pharmacokinetics was unchanged by co-administration with darunavir alone. Ketoconazole AUC(12h), C(max) and C(min) increased by 212% (165, 268), 111% (81, 144) and 868% (544, 1355), respectively, during co-administration with darunavir/ritonavir compared with ketoconazole alone. CONCLUSIONS: The increase in darunavir exposure by ketoconazole was lower than that observed previously with ritonavir. A maximum ketoconazole dose of 200 mg day(-1) is recommended if used concomitantly with darunavir/ritonavir, with no dose adjustments for darunavir/ritonavir.
Pubmed Id: 18460033
11. Hartmann B et al. Drug therapy in patients with chronic renal failure. Deutsches Arzteblatt international. 2010
Authors: Hartmann B Czock D Keller F
Abstract: BACKGROUND: Roughly 20% of patients in hospital have impaired kidney function. This is frequently overlooked because of the creatinine-blind range in which early stages of renal failure are often hidden. Chronic kidney disease is divided into 5 stages (CKD 1 to 5). METHODS: Selective literature search. RESULTS: Methotrexate, enoxaparin and metformin are examples of drugs that should no longer be prescribed if the glomerular filtration rate (GFR) is 60 mL/min or less. With antidiabetic (e.g. glibenclamide), cardiovascular (e.g. atenolol) or anticonvulsive (e.g. gabapentin) drugs, the advice is to use alternative preparations such as gliquidone, metoprolol or carbamazepine which are independent of kidney function. Drug dose adjustment should be considered with antimicrobial (e.g. ampicillin, cefazolin), antiviral (e.g. aciclovir, oseltamivir) and, most recently, also for half of all chemotherapeutic and cytotoxic drugs in patients with impaired kidney function (with e.g. cisplatin, for instance, but not with paclitaxel). CONCLUSION: Decisions concerning drug dose adjustment must be based on the pharmacokinetics but this is an adequate prerequisite only in conjunction with the pharmacodynamics. There are two different dose adjustment rules: proportional dose reduction according to Luzius Dettli, and the half dosage rule according to Calvin Kunin. The latter leads to higher trough concentrations but is probably more efficient for anti-infective therapy.
Pubmed Id: 20959896
12. Marino SE et al. Steady-state carbamazepine pharmacokinetics following oral and stable-labeled intravenous administration in epilepsy patients: effects of race and sex. Clinical pharmacology and therapeutics. 2012
Authors: Marino SE Birnbaum AK Leppik IE Conway JM Musib LC Brundage RC Ramsay RE Pennell PB White JR Gross CR Rarick JO Mishra U Cloyd JC
Abstract: Carbamazepine is a widely prescribed antiepileptic drug. Owing to the lack of an intravenous formulation, its absolute bioavailability, absolute clearance, and half-life in patients at steady state have not been determined. We developed an intravenous, stable-labeled (SL) formulation in order to characterize carbamazepine pharmacokinetics in patients. Ninety-two patients received a 100-mg infusion of SL-carbamazepine as part of their morning dose. Blood samples were collected up to 96 hours after drug administration. Plasma drug concentrations were measured with liquid chromatography-mass spectrometry, and concentration-time data were analyzed using a noncompartmental approach. Absolute clearance (l/hr/kg) was significantly lower in men (0.039 ± 0.017) than in women (0.049 ± 0.018; P = 0.007) and in African Americans (0.039 ± 0.017) when compared with Caucasians (0.048 ± 0.018; P = 0.019). Half-life was significantly longer in men than in women as well as in African Americans as compared with Caucasians. The absolute bioavailability was 0.78. Sex and racial differences in clearance may contribute to variable dosing requirements and clinical response.
Pubmed Id: 22278332
13. Kong ST et al. Clinical validation and implications of dried blood spot sampling of carbamazepine, valproic acid and phenytoin in patients with epilepsy. PloS one. 2014
Authors: Kong ST Lim SH Lee WB Kumar PK Wang HY Ng YL Wong PS Ho PC
Abstract: To facilitate therapeutic monitoring of antiepileptic drugs (AEDs) by healthcare professionals for patients with epilepsy (PWE), we applied a GC-MS assay to measure three AEDs: carbamazepine (CBZ), phenytoin (PHT) and valproic acid (VPA) levels concurrently in one dried blood spot (DBS), and validated the DBS-measured levels to their plasma levels. 169 PWE on either mono- or polytherapy of CBZ, PHT or/and VPA were included. One DBS, containing ∼15 µL of blood, was acquired for the simultaneous measurement of the drug levels using GC-MS. Simple Deming regressions were performed to correlate the DBS levels with the plasma levels determined by the conventional immunoturbimetric assay in clinical practice. Statistical analyses of the results were done using MedCalc Version 12.6.1.0 and SPSS 21. DBS concentrations (Cdbs) were well-correlated to the plasma concentrations (Cplasma): r=0.8381, 0.9305 and 0.8531 for CBZ, PHT and VPA respectively, The conversion formulas from Cdbs to plasma concentrations were [0.89×CdbsCBZ+1.00]µg/mL, [1.11×CdbsPHT-1.00]µg/mL and [0.92×CdbsVPA+12.48]µg/mL respectively. Inclusion of the red blood cells (RBC)/plasma partition ratio (K) and the individual hematocrit levels in the estimation of the theoretical Cplasma from Cdbs of PHT and VPA further improved the identity between the observed and the estimated theoretical Cplasma. Bland-Altman plots indicated that the theoretical and observed Cplasma of PHT and VPA agreed well, and >93.0% of concentrations was within 95% CI (±2SD); and similar agreement (1∶1) was also found between the observed Cdbs and Cplasma of CBZ. As the Cplasma of CBZ, PHT and VPA can be accurately estimated from their Cdbs, DBS can therefore be used for drug monitoring in PWE on any of these AEDs.
Pubmed Id: 25255292
14. Milovanovic DD et al. The influence ofon carbamazepine serum concentration in epileptic pediatric patients. Balkan journal of medical genetics : BJMG. 2016
Authors: Milovanovic DD Milovanovic JR Radovanovic M Radosavljevic I Obradovic S Jankovic S Milovanovic D Djordjevic N
Abstract: The aim of the present study was to investigate the distribution ofvariantsand, as well as their effect on carbamazepine pharmacokinetic properties, in 40 epileptic pediatric patients on carbamazepine treatment. Genotyping was conducted using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), and allele-specific (AS)-PCR methods, and steady-state carbamazepine plasma concentrations were determined by high performance liquid chromatography (HPLC). Theandpolymorphisms were found at frequencies of 17.5 and 0.0%, respectively. After dose adjustment, there was a difference in daily dose incarriers compared to non carriers [mean ± standard deviation (SD): 14.19 ± 5.39. 15.46 ± 4.35 mg/kg;= 0.5]. Dose-normalized serum concentration of carbamazepine was higher in(mean ± SD: 0.54 ± 0.18 vs. 0.43 ± 0.11 mg/mL,= 0.04), and the observed correlation between weight-adjusted carbamazepine dose and carbamazepine concentration after dose adjustment was significant only innon carriers (r = 0.52,= 0.002). However, the population pharmacokinetic analysis failed to demonstrate any significant effect ofpolymorphism on carbamazepine clearance [CL L/h = 0.215 + 0.0696*SEX+ 0.000183*DD]. The results indicated that thepolymorphism might not be of clinical importance for epilepsy treatment in pediatric populations.
Pubmed Id: 27785404
15. Ivanyuk A et al. Renal Drug Transporters and Drug Interactions. Clinical pharmacokinetics. 2017
Authors: Ivanyuk A Livio F Biollaz J Buclin T
Abstract: Transporters in proximal renal tubules contribute to the disposition of numerous drugs. Furthermore, the molecular mechanisms of tubular secretion have been progressively elucidated during the past decades. Organic anions tend to be secreted by the transport proteins OAT1, OAT3 and OATP4C1 on the basolateral side of tubular cells, and multidrug resistance protein (MRP) 2, MRP4, OATP1A2 and breast cancer resistance protein (BCRP) on the apical side. Organic cations are secreted by organic cation transporter (OCT) 2 on the basolateral side, and multidrug and toxic compound extrusion (MATE) proteins MATE1, MATE2/2-K, P-glycoprotein, organic cation and carnitine transporter (OCTN) 1 and OCTN2 on the apical side. Significant drug-drug interactions (DDIs) may affect any of these transporters, altering the clearance and, consequently, the efficacy and/or toxicity of substrate drugs. Interactions at the level of basolateral transporters typically decrease the clearance of the victim drug, causing higher systemic exposure. Interactions at the apical level can also lower drug clearance, but may be associated with higher renal toxicity, due to intracellular accumulation. Whereas the importance of glomerular filtration in drug disposition is largely appreciated among clinicians, DDIs involving renal transporters are less well recognized. This review summarizes current knowledge on the roles, quantitative importance and clinical relevance of these transporters in drug therapy. It proposes an approach based on substrate-inhibitor associations for predicting potential tubular-based DDIs and preventing their adverse consequences. We provide a comprehensive list of known drug interactions with renally-expressed transporters. While many of these interactions have limited clinical consequences, some involving high-risk drugs (e.g. methotrexate) definitely deserve the attention of prescribers.
Pubmed Id: 28210973
16. Cherkaoui-Rbati MH et al. A quantitative systems pharmacology approach, incorporating a novel liver model, for predicting pharmacokinetic drug-drug interactions. PloS one. 2017
Authors: Cherkaoui-Rbati MH Paine SW Littlewood P Rauch C
Abstract: All pharmaceutical companies are required to assess pharmacokinetic drug-drug interactions (DDIs) of new chemical entities (NCEs) and mathematical prediction helps to select the best NCE candidate with regard to adverse effects resulting from a DDI before any costly clinical studies. Most current models assume that the liver is a homogeneous organ where the majority of the metabolism occurs. However, the circulatory system of the liver has a complex hierarchical geometry which distributes xenobiotics throughout the organ. Nevertheless, the lobule (liver unit), located at the end of each branch, is composed of many sinusoids where the blood flow can vary and therefore creates heterogeneity (e.g. drug concentration, enzyme level). A liver model was constructed by describing the geometry of a lobule, where the blood velocity increases toward the central vein, and by modeling the exchange mechanisms between the blood and hepatocytes. Moreover, the three major DDI mechanisms of metabolic enzymes; competitive inhibition, mechanism based inhibition and induction, were accounted for with an undefined number of drugs and/or enzymes. The liver model was incorporated into a physiological-based pharmacokinetic (PBPK) model and simulations produced, that in turn were compared to ten clinical results. The liver model generated a hierarchy of 5 sinusoidal levels and estimated a blood volume of 283 mL and a cell density of 193 × 106 cells/g in the liver. The overall PBPK model predicted the pharmacokinetics of midazolam and the magnitude of the clinical DDI with perpetrator drug(s) including spatial and temporal enzyme levels changes. The model presented herein may reduce costs and the use of laboratory animals and give the opportunity to explore different clinical scenarios, which reduce the risk of adverse events, prior to costly human clinical studies.
Pubmed Id: 28910306
17. Kiesel EK et al. An anticholinergic burden score for German prescribers: score development. BMC geriatrics. 2018
Authors: Kiesel EK Hopf YM Drey M
Abstract: BACKGROUND: Anticholinergic drugs put elderly patients at a higher risk for falls, cognitive decline, and delirium as well as peripheral adverse reactions like dry mouth or constipation. Prescribers are often unaware of the drug-based anticholinergic burden (ACB) of their patients. This study aimed to develop an anticholinergic burden score for drugs licensed in Germany to be used by clinicians at prescribing level. METHODS: A systematic literature search in pubmed assessed previously published ACB tools. Quantitative grading scores were extracted, reduced to drugs available in Germany, and reevaluated by expert discussion. Drugs were scored as having no, weak, moderate, or strong anticholinergic effects. Further drugs were identified in clinical routine and included as well. RESULTS: The literature search identified 692 different drugs, with 548 drugs available in Germany. After exclusion of drugs due to no systemic effect or scoring of drug combinations (n = 67) and evaluation of 26 additional identified drugs in clinical routine, 504 drugs were scored. Of those, 356 drugs were categorised as having no, 104 drugs were scored as weak, 18 as moderate and 29 as having strong anticholinergic effects. CONCLUSIONS: The newly created ACB score for drugs authorized in Germany can be used in daily clinical practice to reduce potentially inappropriate medications for elderly patients. Further clinical studies investigating its effect on reducing anticholinergic side effects are necessary for validation.
Pubmed Id: 30305048

epha.ch AG

Stadelhoferstrasse 40 8001 Zúrich Suiza
Github LinkedIn Facebook Twitter
kontakt@epha.ch

General

Huella Política de privacidad Condiciones de uso Acerca de nosotros API

Idiomas

Deutsch English Français Italiano Español
Copyright © 2020 epha.ch - Todos los derechos reservados